New Leaf Venture Partners, L.L.C. Crinetics Pharmaceuticals, Inc. Transaction History
New Leaf Venture Partners, L.L.C.
- $74.2 Million
- Q4 2024
A detailed history of New Leaf Venture Partners, L.L.C. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, New Leaf Venture Partners, L.L.C. holds 141,000 shares of CRNX stock, worth $4.96 Million. This represents 9.72% of its overall portfolio holdings.
Number of Shares
141,000
Previous 141,000
-0.0%
Holding current value
$4.96 Million
Previous $7.2 Million
0.1%
% of portfolio
9.72%
Previous 7.43%
Shares
2 transactions
Others Institutions Holding CRNX
# of Institutions
255Shares Held
89.5MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$320 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.95MShares$245 Million0.07% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$219 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$216 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$191 Million0.03% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.89B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...